VISTAGEN THERAPEUTICS, INC.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.3M | $486.0K | $1.1M | $-227.0K | $1.1M | $1.1M | $0 | $0 |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $55.0M | $39.4M | $20.0M | $44.4M | $35.4M | $11.9M | $13.4M | $7.8M |
| SG&A Expense | $18.4M | $17.1M | $14.1M | $14.7M | $13.5M | $7.1M | $7.4M | $6.4M |
| Operating Income | $-72.1M | $-56.0M | $-33.0M | $-59.3M | $-47.8M | $-17.9M | $-20.8M | $-14.2M |
| Operating Margin | -5,683.7% | -11,517.1% | -3,103.5% | 26,109.3% | -4,308.3% | -1,646.1% | — | — |
| Interest Expense | — | — | — | — | — | — | — | $8.9K |
| Pretax Income | $-69.7M | $-51.4M | $-29.4M | $-59.2M | $-47.8M | $-17.9M | $-20.8M | $-14.3M |
| Income Tax Expense | $7.0K | $7.0K | $4.0K | $6.0K | $3.4K | $2.6K | $2.6K | $2.4K |
| Net Income | $-69.7M | $-51.4M | $-29.4M | $-59.2M | $-47.8M | $-17.9M | $-20.8M | $-14.3M |
| Net Margin | -5,491.3% | -10,579.8% | -2,759.6% | 26,100.4% | -4,306.8% | -1,646.1% | — | — |
| EPS (Basic) | $-1.83 | $-1.67 | $-1.52 | $-2.84 | $-2.46 | $-0.16 | $-0.17 | $-0.37 |
| EPS (Diluted) | $-1.83 | $-1.67 | $-1.52 | $-2.84 | — | $-0.16 | $-0.17 | $-0.37 |
| Shares Outstanding (Basic) | 38.1M | 30.9M | 19.4M | 20.9M | 19.8M | 258.4M | 167.3M | 69.1M |
| Shares Outstanding (Diluted) | 38.1M | 30.9M | 19.4M | 20.9M | 19.8M | 258.4M | 167.3M | 69.1M |
| Dividends Per Share | — | — | — | — | — | — | — | — |